Cargando…

STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel

The Six Transmembrane Epithelial Antigen of the Prostate 1 (STEAP1) protein has been indicated as an overexpressed oncoprotein in prostate cancer (PCa), associated with tumor progression and aggressiveness. Taxane-based antineoplastic drugs such as paclitaxel, docetaxel, or cabazitaxel, have been in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rocha, Sandra M., Nascimento, Daniel, Coelho, Rafaella S., Cardoso, Ana Margarida, Passarinha, Luís A., Socorro, Sílvia, Maia, Cláudio J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095014/ https://www.ncbi.nlm.nih.gov/pubmed/37047621 http://dx.doi.org/10.3390/ijms24076643

Ejemplares similares

STEAP1 regulation and its influence modulating the response of LNCaP prostate cancer cells to bicalutamide, enzalutamide and apalutamide
por: Rocha, Sandra M., et al.
Publicado: (2023)

Promoter Demethylation Upregulates STEAP1 Gene Expression in Human Prostate Cancer: In Vitro and In Silico Analysis
por: Rocha, Sandra M., et al.
Publicado: (2021)

STEAP1 expression in prostate cancer and its regulation by androgens
por: Gomes, Inês, et al.
Publicado: (2010)

Expression of STEAP1 and STEAP1B in prostate cell lines, and the putative regulation of STEAP1 by post-transcriptional and post-translational mechanisms
por: Gomes, Inês M., et al.
Publicado: (2014)

Enhanced Stability of Detergent-Free Human Native STEAP1 Protein from Neoplastic Prostate Cancer Cells upon an Innovative Isolation Procedure
por: Barroca-Ferreira, Jorge, et al.
Publicado: (2021)

TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer
por: Sekino, Yohei, et al.
Publicado: (2019)

STEAP2 Knockdown Reduces the Invasive Potential of Prostate Cancer Cells
por: Burnell, Stephanie E. A., et al.
Publicado: (2018)

Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel
por: Sousa-Pimenta, Mário, et al.
Publicado: (2023)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022)

Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer
por: Calcagno, Fabien, et al.
Publicado: (2012)

Influence of response to prior docetaxel on sensitivity to cabazitaxel in prostate cancer patients with PTEN alterations
por: Kamisawa, Ken, et al.
Publicado: (2022)

Pleuropulmonary and Lymph Node Progression after Docetaxel – Benefits from Treatment with Cabazitaxel in Metastatic Prostate Cancer
por: Huerta, Angel Segura, et al.
Publicado: (2013)

The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients
por: Terada, Naoki, et al.
Publicado: (2019)

An observational, multicentre study of cabazitaxel in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel (CAPRISTANA)
por: Carles, Joan, et al.
Publicado: (2018)

No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer
por: Kosaka, Takeo, et al.
Publicado: (2018)

Expression and prognostic analyses of the significance of STEAP1 and STEAP2 in lung cancer
por: Liu, Tianshu, et al.
Publicado: (2022)

Clinical significance of STEAP1 extracellular vesicles in prostate cancer
por: Khanna, Karan, et al.
Publicado: (2021)

Initial treatment outcome and feasibility of low-dose cabazitaxel against docetaxel- and castration-resistant prostate cancer in a Japanese hospital
por: Chaya, Ryosuke, et al.
Publicado: (2020)

Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance
por: Zhang, Peng-Fei, et al.
Publicado: (2021)

Feasibility of cabazitaxel in octogenarian prostate cancer patients
por: Tralongo, Paolo, et al.
Publicado: (2023)

Role of microRNAs in the resistance of prostate cancer to docetaxel and paclitaxel
por: Kopczyńska, Ewa
Publicado: (2016)

Critical appraisal of cabazitaxel in the management of advanced prostate cancer
por: Pal, Sumanta Kumar, et al.
Publicado: (2010)

Targeting STEAP1 as an anticancer strategy
por: Nakamura, Hajime, et al.
Publicado: (2023)

Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen
por: Fryzek, Jon P., et al.
Publicado: (2018)

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
por: Massard, C., et al.
Publicado: (2017)

Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer
por: Tsao, Che-Kai, et al.
Publicado: (2011)

Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer
por: Di Lorenzo, Giuseppe, et al.
Publicado: (2016)

Cabazitaxel Induced Thrombotic Microangiopathy in a Patient with Prostate Cancer
por: Nlandu, Yannick, et al.
Publicado: (2019)

Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer
por: Pobel, Cedric, et al.
Publicado: (2021)

Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2021)

Preclinical profile of cabazitaxel
por: Vrignaud, Patricia, et al.
Publicado: (2014)

Investigation of enzalutamide, docetaxel, and cabazitaxel resistance in the castration resistant prostate cancer cell line C4 using genome-wide CRISPR/Cas9 screening
por: Haldrup, Jakob, et al.
Publicado: (2023)

Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines
por: Machioka, Kazuaki, et al.
Publicado: (2018)

Analysis of cabazitaxel‐resistant mechanism in human castration‐resistant prostate cancer
por: Hongo, Hiroshi, et al.
Publicado: (2018)

Safety and efficacy of cabazitaxel in Japanese patients with castration-resistant prostate cancer
por: Yamamoto, Teppei, et al.
Publicado: (2020)

Continued Androgen Signalling Inhibition improves Cabazitaxel Efficacy in Prostate Cancer
por: Mout, Lisanne, et al.
Publicado: (2021)

STEAP1–4 (Six-Transmembrane Epithelial Antigen of the Prostate 1–4) and Their Clinical Implications for Prostate Cancer
por: Xu, Michael, et al.
Publicado: (2022)

Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel()
por: de Leon, Maria C.B., et al.
Publicado: (2013)

Mechanism of stepwise electron transfer in six-transmembrane epithelial antigen of the prostate (STEAP) 1 and 2
por: Chen, Kehan, et al.
Publicado: (2023)

Sequencing of Cabazitaxel in Metastatic Castrate-Resistant Prostate Cancer: A Case Report
por: Colbourn, Donald
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_cqs428k0sq1o5pi5ekj1ek72id